Answers are grounded in this paper and cite their sources.
Randomized trial shows reduced diffusion with ARIA in patients treated with donanemab, indicating important clinical significance.
ε3/ε3, ε4/ε4, and ε3/ε4, respectively) - who developed ARIA accompanied by transient foci of reduced diffusion within the first six months of donanemab treatment, without permanent T2/FLAIR correlates. The diffusion-restricting lesions may represent ischemic infarcts, although the lack of permanent T2/FLAIR correlate is atypical. Clinicians should be aware that reduced diffusion may accompany ARIA. The course can be highly dynamic, and both the clinical presentation and management implications may vary.
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: